De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
DCPH Overzicht aandelen
A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
Sneeuwvlok Score | |
---|---|
Waardering | 2/6 |
Toekomstige groei | 2/6 |
Prestaties in het verleden | 0/6 |
Financiële gezondheid | 6/6 |
Dividenden | 0/6 |
Beloningen
Risicoanalyse
Deciphera Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
Historische aandelenkoersen | |
---|---|
Huidige aandelenkoers | US$25.59 |
52 Week Hoogtepunt | US$25.61 |
52 Week Laag | US$9.90 |
Bèta | 0.18 |
11 maand verandering | 0.91% |
3 maanden verandering | 60.14% |
1 Jaar Verandering | 76.48% |
33 jaar verandering | -28.68% |
5 jaar verandering | 6.71% |
Verandering sinds IPO | 44.99% |
Recent nieuws en updates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Rendement voor aandeelhouders
DCPH | US Biotechs | US Markt | |
---|---|---|---|
7D | 0.08% | -0.2% | -0.4% |
1Y | 76.5% | 22.1% | 34.1% |
Rendement versus industrie: DCPH overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.1 % opleverde.
Rendement versus markt: DCPH overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.
Prijsvolatiliteit
DCPH volatility | |
---|---|
DCPH Average Weekly Movement | 20.9% |
Biotechs Industry Average Movement | 10.0% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van DCPH is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van DCPH is het afgelopen jaar gestegen van 12% naar 21%.
Over het bedrijf
Opgericht | Werknemers | CEO | Website |
---|---|---|---|
2003 | 355 | Steve Hoerter | www.deciphera.com |
Deciphera Pharmaceuticals, Inc. Samenvatting
DCPH fundamentele statistieken | |
---|---|
Marktkapitalisatie | US$2.21b |
Inkomsten(TTM) | -US$190.42m |
Inkomsten(TTM) | US$174.91m |
12.7x
P/S-verhouding-11.6x
Koers/WinstverhoudingIs DCPH overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
DCPH resultatenrekening (TTM) | |
---|---|
Inkomsten | US$174.91m |
Kosten van inkomsten | US$242.52m |
Brutowinst | -US$67.61m |
Overige uitgaven | US$122.80m |
Inkomsten | -US$190.42m |
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) | -2.20 |
Brutomarge | -38.66% |
Nettowinstmarge | -108.87% |
Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde DCPH op de lange termijn?
Bekijk historische prestaties en vergelijking